Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Articles by Allissa M. Long, PharmD and Kevin W. Chamberlin, PharmD, FASCP
Advertisement
Latest Updated Articles
Lefamulin (Xenleta) for Community Acquired Bacterial PneumoniaPublished: January 21st 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Expands Approval of Flibanserin for Postmenopausal Women’s Sexual Health
2
Why Trump’s Second Term is Different for the MFN Drug Pricing Policy
3
Pharmacists Can Play Central Role in Patients’ Infusion Services | ASHP Midyear 2025
4
Greater Coordination, Integration Necessary for Pregnant Women With Epilepsy
5
